PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1484660
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1484660
Isothermal Nucleic Acid Amplification Technology Market Size Report by Product, Technology, Application, End User - Global Industry Growth Forecast to 2030
Market Overview
The global isothermal nucleic acid amplification technology market generated revenue of USD 4,425.5 million in 2023 and is expected to witness a CAGR of 9.4% during 2024-2030, reaching USD 8,159.4 million by 2030. This growth is attributed to the significant increase in its usage as a molecular testing technique due to the rising prevalence of infectious diseases, including tuberculosis, hepatitis, and influenza, which are among the leading causes of death, particularly in developing countries.
Tuberculosis, hepatitis, and flu are diseases transmitted by way of infectious diseases in which the leading cause of death is mostly observed in underdeveloped countries.
a bewildering range of diagnostic tests combined with an increasing number of Emergency Use Authorizations for CLIA-waived tests are spurring the development of the isothermal nucleic acid amplification technology market. These tests being free of complex procedures, lesser chances of error, and being able to personalize the dose on patients are a few instances of why these tests remain so popular.
These technologies have various uses such as gene manipulation that is done with recombinant DNA and similar molecular biology practices. It is a new way to detect prepare and analyze a small number of nucleic acids containing DNA or RNA that enter into cells.
Historically, there has never been a life history that was free from infectious diseases and this has continued to be a major cause of death and disability. With the increasing incidences of communicable diseases around the world which as weighty factors in the market expansion, this field is seeing major growth nowadays.
Key Insights
In 2023, the consumables category led the isothermal nucleic acid amplification technology industry, with a 70% revenue share, projected to uphold supremacy.
The wide use of reagents in diagnostic laboratories and major healthcare settings contributes to this supremacy.
Obtainability of polymerases with high strand displacement abilities further boosts demand for consumables.
Companies are making numerous reagents to sense communicable diseases, confronting the growing occurrence.
Increasing cases of cardiovascular illnesses, diabetes, and cholesterol-linked illnesses drive the growth of convenient POC diagnostic devices.
The instruments category is expected to show the fastest growth due to increased R&D investments in novel diagnostic techniques for infectious diseases like COVID-19.
In 2023, the hospital's category led with a 60% share in the INAAT industry, projected to uphold supremacy because of the augmented usage of miniaturized POC instruments.
Increased throughput and automation capabilities of INAAT technologies for processing large sample volumes are expected to drive segment growth.
Diagnostic centers forecast the highest CAGR due to rising numbers and the adoption of molecular techniques for early disease detection, supported by funding from public agencies for infectious disease mitigation.
North America held around 45% of the market in 2023, poised for robust growth due to established research infrastructure and demand for nucleic-acid-amplification-based diagnostics.
High per capita healthcare spending and interest in point-of-care diagnostics drive market expansion in North America.
In 2023, loop-mediated amplification dominated the INAAT industry with a 40% revenue share, projected to uphold supremacy.
LAMP technology upgrades allow highly directive, productive, and fast in-situ DNA manufacturing process under isothermal conditions.
There recruitation of DNA polymerase and four primer adds protrusion of six different motifs on target DNA in DNA replication.
The kit is a microbial identification method which includes three types of detection techniques (lateral flow, agarose gel detection, and real-time fluorescence with intercalators)
LAMP against PCR's resistance to interactive molecules is that samples can be used even in the less purified form.
It has a potential for testing all RNA and DNA sequences at the same time and is capable of detecting both Zika and SARS-CoV-2 viruses in human specimens.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by product
- 1.4.2. Market size breakdown, by technology
- 1.4.3. Market size breakdown, by application
- 1.4.4. Market size breakdown, by end user
- 1.4.5. Market size breakdown, by region
- 1.4.6. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.5.1. Value
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
- 5.2. Impact of COVID-19
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes
Chapter 6. Global Market
- 6.1. Overview
- 6.2. Market Revenue, by Product (2017-2030)
- 6.3. Market Revenue, by Technology (2017-2030)
- 6.4. Market Revenue, by Application (2017-2030)
- 6.5. Market Revenue, by End User (2017-2030)
- 6.6. Market Revenue, by Region (2017-2030)
Chapter 7. North America Market
- 7.1. Overview
- 7.2. Market Revenue, by Product (2017-2030)
- 7.3. Market Revenue, by Technology (2017-2030)
- 7.4. Market Revenue, by Application (2017-2030)
- 7.5. Market Revenue, by End User (2017-2030)
- 7.6. Market Revenue, by Country (2017-2030)
Chapter 8. Europe Market
- 8.1. Overview
- 8.2. Market Revenue, by Product (2017-2030)
- 8.3. Market Revenue, by Technology (2017-2030)
- 8.4. Market Revenue, by Application (2017-2030)
- 8.5. Market Revenue, by End User (2017-2030)
- 8.6. Market Revenue, by Country (2017-2030)
Chapter 9. APAC Market
- 9.1. Overview
- 9.2. Market Revenue, by Product (2017-2030)
- 9.3. Market Revenue, by Technology (2017-2030)
- 9.4. Market Revenue, by Application (2017-2030)
- 9.5. Market Revenue, by End User (2017-2030)
- 9.6. Market Revenue, by Country (2017-2030)
Chapter 10. LATAM Market
- 10.1. Overview
- 10.2. Market Revenue, by Product (2017-2030)
- 10.3. Market Revenue, by Technology (2017-2030)
- 10.4. Market Revenue, by Application (2017-2030)
- 10.5. Market Revenue, by End User (2017-2030)
- 10.6. Market Revenue, by Country (2017-2030)
Chapter 11. MEA Market
- 11.1. Overview
- 11.2. Market Revenue, by Product (2017-2030)
- 11.3. Market Revenue, by Technology (2017-2030)
- 11.4. Market Revenue, by Application (2017-2030)
- 11.5. Market Revenue, by End User (2017-2030)
- 11.6. Market Revenue, by Country (2017-2030)
Chapter 12. U.S. Market
- 12.1. Overview
- 12.2. Market Revenue, by Product (2017-2030)
- 12.3. Market Revenue, by Technology (2017-2030)
- 12.4. Market Revenue, by Application (2017-2030)
- 12.5. Market Revenue, by End User (2017-2030)
Chapter 13. Canada Market
- 13.1. Overview
- 13.2. Market Revenue, by Product (2017-2030)
- 13.3. Market Revenue, by Technology (2017-2030)
- 13.4. Market Revenue, by Application (2017-2030)
- 13.5. Market Revenue, by End User (2017-2030)
Chapter 14. Germany Market
- 14.1. Overview
- 14.2. Market Revenue, by Product (2017-2030)
- 14.3. Market Revenue, by Technology (2017-2030)
- 14.4. Market Revenue, by Application (2017-2030)
- 14.5. Market Revenue, by End User (2017-2030)
Chapter 15. France Market
- 15.1. Overview
- 15.2. Market Revenue, by Product (2017-2030)
- 15.3. Market Revenue, by Technology (2017-2030)
- 15.4. Market Revenue, by Application (2017-2030)
- 15.5. Market Revenue, by End User (2017-2030)
Chapter 16. U.K. Market
- 16.1. Overview
- 16.2. Market Revenue, by Product (2017-2030)
- 16.3. Market Revenue, by Technology (2017-2030)
- 16.4. Market Revenue, by Application (2017-2030)
- 16.5. Market Revenue, by End User (2017-2030)
Chapter 17. Italy Market
- 17.1. Overview
- 17.2. Market Revenue, by Product (2017-2030)
- 17.3. Market Revenue, by Technology (2017-2030)
- 17.4. Market Revenue, by Application (2017-2030)
- 17.5. Market Revenue, by End User (2017-2030)
Chapter 18. Spain Market
- 18.1. Overview
- 18.2. Market Revenue, by Product (2017-2030)
- 18.3. Market Revenue, by Technology (2017-2030)
- 18.4. Market Revenue, by Application (2017-2030)
- 18.5. Market Revenue, by End User (2017-2030)
Chapter 19. Japan Market
- 19.1. Overview
- 19.2. Market Revenue, by Product (2017-2030)
- 19.3. Market Revenue, by Technology (2017-2030)
- 19.4. Market Revenue, by Application (2017-2030)
- 19.5. Market Revenue, by End User (2017-2030)
Chapter 20. China Market
- 20.1. Overview
- 20.2. Market Revenue, by Product (2017-2030)
- 20.3. Market Revenue, by Technology (2017-2030)
- 20.4. Market Revenue, by Application (2017-2030)
- 20.5. Market Revenue, by End User (2017-2030)
Chapter 21. India Market
- 21.1. Overview
- 21.2. Market Revenue, by Product (2017-2030)
- 21.3. Market Revenue, by Technology (2017-2030)
- 21.4. Market Revenue, by Application (2017-2030)
- 21.5. Market Revenue, by End User (2017-2030)
Chapter 22. Australia Market
- 22.1. Overview
- 22.2. Market Revenue, by Product (2017-2030)
- 22.3. Market Revenue, by Technology (2017-2030)
- 22.4. Market Revenue, by Application (2017-2030)
- 22.5. Market Revenue, by End User (2017-2030)
Chapter 23. South Korea Market
- 23.1. Overview
- 23.2. Market Revenue, by Product (2017-2030)
- 23.3. Market Revenue, by Technology (2017-2030)
- 23.4. Market Revenue, by Application (2017-2030)
- 23.5. Market Revenue, by End User (2017-2030)
Chapter 24. Brazil Market
- 24.1. Overview
- 24.2. Market Revenue, by Product (2017-2030)
- 24.3. Market Revenue, by Technology (2017-2030)
- 24.4. Market Revenue, by Application (2017-2030)
- 24.5. Market Revenue, by End User (2017-2030)
Chapter 25. Mexico Market
- 25.1. Overview
- 25.2. Market Revenue, by Product (2017-2030)
- 25.3. Market Revenue, by Technology (2017-2030)
- 25.4. Market Revenue, by Application (2017-2030)
- 25.5. Market Revenue, by End User (2017-2030)
Chapter 26. Saudi Arabia Market
- 26.1. Overview
- 26.2. Market Revenue, by Product (2017-2030)
- 26.3. Market Revenue, by Technology (2017-2030)
- 26.4. Market Revenue, by Application (2017-2030)
- 26.5. Market Revenue, by End User (2017-2030)
Chapter 27. South Africa Market
- 27.1. Overview
- 27.2. Market Revenue, by Product (2017-2030)
- 27.3. Market Revenue, by Technology (2017-2030)
- 27.4. Market Revenue, by Application (2017-2030)
- 27.5. Market Revenue, by End User (2017-2030)
Chapter 28. U.A.E. Market
- 28.1. Overview
- 28.2. Market Revenue, by Product (2017-2030)
- 28.3. Market Revenue, by Technology (2017-2030)
- 28.4. Market Revenue, by Application (2017-2030)
- 28.5. Market Revenue, by End User (2017-2030)
Chapter 29. Competitive Landscape
- 29.1. List of Market Players and their Offerings
- 29.2. Competitive Benchmarking of Key Players
- 29.3. Product Benchmarking of Key Players
- 29.4. Recent Strategic Developments
Chapter 30. Company Profiles
- 30.1. Becton, Dickinson and Company
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
- 30.2. QIAGEN N.V.
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
- 30.3. Quidel Corporation
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
- 30.4. bioMerieux SA
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
- 30.5. Abbott Laboratories
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
- 30.6. Meridian Bioscience Inc.
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
- 30.7. Thermo Fisher Scientific Inc.
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
- 30.8. Atila Biosystems
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
- 30.9. Grifols S.A.
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary
- 30.10. Eiken Chemical Co. Ltd.
- 30.10.1. Business overview
- 30.10.2. Product and service offerings
- 30.10.3. Key financial summary
Chapter 31. Appendix
- 31.1. Abbreviations
- 31.2. Sources and References
- 31.3. Related Reports
